» Articles » PMID: 17251933

Senescence and Tumour Clearance is Triggered by P53 Restoration in Murine Liver Carcinomas

Overview
Journal Nature
Specialty Science
Date 2007 Jan 26
PMID 17251933
Citations 1265
Authors
Affiliations
Soon will be listed here.
Abstract

Although cancer arises from a combination of mutations in oncogenes and tumour suppressor genes, the extent to which tumour suppressor gene loss is required for maintaining established tumours is poorly understood. p53 is an important tumour suppressor that acts to restrict proliferation in response to DNA damage or deregulation of mitogenic oncogenes, by leading to the induction of various cell cycle checkpoints, apoptosis or cellular senescence. Consequently, p53 mutations increase cell proliferation and survival, and in some settings promote genomic instability and resistance to certain chemotherapies. To determine the consequences of reactivating the p53 pathway in tumours, we used RNA interference (RNAi) to conditionally regulate endogenous p53 expression in a mosaic mouse model of liver carcinoma. We show that even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions. The primary response to p53 was not apoptosis, but instead involved the induction of a cellular senescence program that was associated with differentiation and the upregulation of inflammatory cytokines. This program, although producing only cell cycle arrest in vitro, also triggered an innate immune response that targeted the tumour cells in vivo, thereby contributing to tumour clearance. Our study indicates that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.

Citing Articles

Targeting the secretory program of 3q-amplified lung cancers.

Pardo L, Norman J J Clin Invest. 2025; 134(12).

PMID: 40047887 PMC: 11178543. DOI: 10.1172/JCI181798.


Bidirectional regulation of the cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon gene pathway and its impact on hepatocellular carcinoma.

Nie A, Xiao Z, Deng J, Li N, Hao L, Li S World J Gastrointest Oncol. 2025; 17(2):98556.

PMID: 39958554 PMC: 11755995. DOI: 10.4251/wjgo.v17.i2.98556.


Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.

Shou S, Maolan A, Zhang D, Jiang X, Liu F, Li Y Exp Hematol Oncol. 2025; 14(1):8.

PMID: 39871386 PMC: 11771031. DOI: 10.1186/s40164-025-00597-9.


Tp53 determines the spatial dynamics of M1/M2 tumor-associated macrophages and M1-driven tumoricidal effects.

Hsiao Y, Hsieh M, Chang G, Hsu Y, Wang C, Chen Y Cell Death Dis. 2025; 16(1):38.

PMID: 39843434 PMC: 11754596. DOI: 10.1038/s41419-025-07346-0.


SMARCA4 regulates the NK-mediated killing of senescent cells.

Reen V, DAmbrosio M, Sogaard P, Tyson K, Leeke B, Clement I Sci Adv. 2025; 11(3):eadn2811.

PMID: 39813356 PMC: 11734740. DOI: 10.1126/sciadv.adn2811.


References
1.
Minamino T, Yoshida T, Tateno K, Miyauchi H, Zou Y, Toko H . Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation. 2003; 108(18):2264-9. DOI: 10.1161/01.CIR.0000093274.82929.22. View

2.
Hong F, Hansen R, Yan J, Allendorf D, Baran J, Ostroff G . Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 2003; 63(24):9023-31. View

3.
Staib F, Hussain S, Hofseth L, Wang X, Harris C . TP53 and liver carcinogenesis. Hum Mutat. 2003; 21(3):201-16. DOI: 10.1002/humu.10176. View

4.
Serrano M, Lin A, McCurrach M, Beach D, Lowe S . Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5):593-602. DOI: 10.1016/s0092-8674(00)81902-9. View

5.
Ventura A, Kirsch D, McLaughlin M, Tuveson D, Grimm J, Lintault L . Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-5. DOI: 10.1038/nature05541. View